Showing 1 - 10 of 86
We study the causal impact of invalidating marginally valid patents during post-grant opposition at the European Patent Office on affected inventors' subsequent patenting. We exploit exogenous variation in invalidation by leveraging the participation of a patent's original examiner in the...
Persistent link: https://www.econbiz.de/10012033571
This paper shows that inventors with an early patenting success have a higher inventive productivity during their remaining career. We use European patent data for a period of 32 years for 1240 German inventors. The patent data are linked with survey data that provide information on an extensive...
Persistent link: https://www.econbiz.de/10012510353
Persistent link: https://www.econbiz.de/10009745077
Persistent link: https://www.econbiz.de/10009298230
Persistent link: https://www.econbiz.de/10003842014
From a firm’s perspective two competing forces are driving the decision to invest in innovation. On the one hand, innovative performance is an important driver of profitability and growth. On the other hand, investments in innovation suffer from negative externalities, i.e. spillovers to other...
Persistent link: https://www.econbiz.de/10012623469
We document the occurrence of process claims in granted U.S. patents over the last century. Using novel data on the type of independent patent claims, we show an increase in the annual share of process claims of about 25 percentage points (from below 10% in 1920). This rise in process intensity...
Persistent link: https://www.econbiz.de/10013175193
Standard-essential patents (SEPs) have become a key element of technical coordination in standard-setting organizations. Yet, in many cases, it remains unclear whether a declared SEP is truly standard-essential. To date, there is no automated procedure that allows for a scalable and objective...
Persistent link: https://www.econbiz.de/10012500157
We analyze the extent to which private defensive litigation insurance deters patent assertion by non-practicing entities (NPEs). We study the effect that a patent-specific defensive insurance product, offered by a leading litigation insurer, had on the litigation behavior of insured patents’...
Persistent link: https://www.econbiz.de/10012267115
Pharmaceutical firms typically enjoy market exclusivity for new drugs from concurrent protection of the underlying invention (through patents) and the clinical trials data submitted for market approval (through data exclusivity). Patent invalidation during drug development renders data...
Persistent link: https://www.econbiz.de/10012064786